Author:
de Kruif J. Th. C. M.,Visser M.,van den Berg M. M. G. A.,Derks M. J. M.,de Boer M. R.,van Laarhoven H. W. M.,de Vries J. H. M.,de Vries Y. C.,Kampman E.,Winkels R. W.,Westerman M. J.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference81 articles.
1. World Cancer Research Fund: Data on specific cancers
https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics
. Accessed 20 May 2018.
2. Nederlandse Kankerregistratie.
https://www.cijfersoverkanker.nl
. Accessed May 4, 2018.
3. Sukel MPP, van de Poll-Franse LV, Nieuwenhuijzen GAP, Vreugdenhil G, Herings RMC, Coebergh JWW, Voogd AC. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer. 2008;13:1846–54.
4. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, Santaquilani M. The EUROCARE working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. The Lancet oncology. 2007;9:773–83.
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.